MA22814A1 - Procede de preparation de derives d'imidazole a chaine laterale biphenylsulfonyluree ou biphenylsulfonylurethanne. - Google Patents

Procede de preparation de derives d'imidazole a chaine laterale biphenylsulfonyluree ou biphenylsulfonylurethanne.

Info

Publication number: MA22814A1
Authority: MA; Morocco
Prior art keywords: biphenylsulfonylurethane; biphenylsulfonylurea; preparation; side chain; imidazole derivatives
Prior art date: 1992-03-07

Application number

MA23107A

Other languages

English (en)

Inventor

Heitsch Holger

Henning Rainer

Wagner Adalbert

Gerhards Hermann

Scholkens Bernward

Becker Reinhard

Original Assignee

Hoechst Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-03-07

Filing date

1993-03-05

Publication date

1993-10-01

1993-03-05 Application filed by Hoechst Ag filed Critical Hoechst Ag

1993-10-01 Publication of MA22814A1 publication Critical patent/MA22814A1/fr

Links

GYWDYDOMTVIFPI-UHFFFAOYSA-N (2-phenylphenyl)sulfonylurea Chemical compound NC(=O)NS(=O)(=O)C1=CC=CC=C1C1=CC=CC=C1 GYWDYDOMTVIFPI-UHFFFAOYSA-N 0.000 title 1
RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
NEESMEYXOMGEIC-UHFFFAOYSA-N ethyl n-(2-phenylphenyl)sulfonylcarbamate Chemical group CCOC(=O)NS(=O)(=O)C1=CC=CC=C1C1=CC=CC=C1 NEESMEYXOMGEIC-UHFFFAOYSA-N 0.000 title 1
229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title 1
102000008873 Angiotensin II receptor Human genes 0.000 abstract 1
108050000824 Angiotensin II receptor Proteins 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Cephalosporin Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

MA23107A 1992-03-07 1993-03-05 Procede de preparation de derives d'imidazole a chaine laterale biphenylsulfonyluree ou biphenylsulfonylurethanne. MA22814A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE4207241		1992-03-07

Publications (1)

Publication Number	Publication Date
MA22814A1 true MA22814A1 (fr)	1993-10-01

Family

ID=6453463

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA23107A MA22814A1 (fr)	1992-03-07	1993-03-05	Procede de preparation de derives d'imidazole a chaine laterale biphenylsulfonyluree ou biphenylsulfonylurethanne.

Country Status (25)

Country	Link
US (1)	US5604251A (fr)
EP (1)	EP0560177B1 (fr)
JP (1)	JP3542813B2 (fr)
KR (1)	KR930019637A (fr)
CN (1)	CN1036341C (fr)
AT (1)	ATE230732T1 (fr)
AU (1)	AU663565B2 (fr)
BR (1)	BR9300761A (fr)
CA (1)	CA2091135A1 (fr)
CZ (1)	CZ281983B6 (fr)
DE (1)	DE59310323D1 (fr)
DK (1)	DK0560177T3 (fr)
ES (1)	ES2187501T3 (fr)
FI (1)	FI930970A7 (fr)
HU (1)	HUT64041A (fr)
IL (1)	IL104971A0 (fr)
MA (1)	MA22814A1 (fr)
NO (1)	NO303632B1 (fr)
NZ (1)	NZ247059A (fr)
PH (1)	PH31466A (fr)
PL (1)	PL173023B1 (fr)
RU (1)	RU2116300C1 (fr)
SK (1)	SK279109B6 (fr)
TW (1)	TW215434B (fr)
ZA (1)	ZA931585B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4010797A1 (de) *	1990-04-04	1991-10-10	Hoechst Ag	Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
US5514696A (en) *	1992-05-06	1996-05-07	Bristol-Myers Squibb Co.	Phenyl sulfonamide endothelin antagonists
CA2111662C (fr) *	1992-12-17	2004-11-23	Hiroaki Yanagisawa	Derives de biphenyles, leur preparation et leur utilisation pour le traitement de l'hypertension et des maladies cardiaques
FR2716883B1 (fr) *	1994-03-04	1996-04-26	Roussel Uclaf	Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
FR2716882B1 (fr) *	1994-03-04	1996-04-05	Roussel Uclaf	Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
US5612359A (en) *	1994-08-26	1997-03-18	Bristol-Myers Squibb Company	Substituted biphenyl isoxazole sulfonamides
US5760038A (en) *	1995-02-06	1998-06-02	Bristol-Myers Squibb Company	Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) *	1995-02-06	1998-07-14	Bristol-Myers Squibb Company	Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) *	1995-07-24	1998-12-08	Bristol-Myers Squibb Co.	Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja)	1995-10-11	1997-05-13	Bristol Myers Squibb Co	置換ビフェニルスルホンアミドエンドセリン拮抗剤
US5856507A (en) *	1997-01-21	1999-01-05	Bristol-Myers Squibb Co.	Methods for the preparation of biphenyl isoxazole sulfonamides
BR9708151A (pt)	1996-02-20	1999-07-27	Bristol Myers Squibb Co	Processo para a preparaç o de bifenil isoxazol sulfonamidas
US5939446A (en) *	1996-04-09	1999-08-17	Bristol-Myers Squibb Co.	Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
DE69734832T2 (de) *	1996-12-13	2006-08-31	Zymogenetics, Inc., Seattle	Zusammensetzungen und verfahren zum stimulieren von knochenwachstum
EP0855392A3 (fr)	1997-01-22	2000-01-05	Hoechst Aktiengesellschaft	Hétérocycles à cinq chaínons contenant des substituants biphénylylsulphoniques, leur procédé de préparation, leur utilisation comme médicament ou agent diagnostique ainsi que médicament les contenant
TW536540B (en) *	1997-01-30	2003-06-11	Bristol Myers Squibb Co	Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
AU6187898A (en) *	1997-01-30	1998-08-25	Bristol-Myers Squibb Company	Method for preventing or treating low renin hypertension by administering an endothelin antagonist
AU748334B2 (en)	1997-10-16	2002-05-30	Board Of Regents, The University Of Texas System	Models and treatments for cardiac hypertrophy in relation with NF-AT3 function
DE19802969A1 (de)	1998-01-27	1999-07-29	Hoechst Marion Roussel De Gmbh	Verfahren zur Herstellung von S-Alkyl(Aryl)-substituierten Imidazol-Derivaten
DE19820064A1 (de) *	1998-05-06	1999-11-11	Hoechst Marion Roussel De Gmbh	Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE19832429A1 (de) *	1998-07-18	2000-01-20	Hoechst Marion Roussel De Gmbh	Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19832428A1 (de) *	1998-07-18	2000-01-20	Hoechst Marion Roussel De Gmbh	Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP1165472A4 (fr)	1999-03-19	2002-11-20	Bristol Myers Squibb Co	Procedes pour la preparation de diphenylisoxazolesulfonamides
US20040106647A1 (en) *	2002-06-28	2004-06-03	Schneider Michael D.	Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
WO2004002226A1 (fr) *	2002-06-28	2004-01-08	Baylor College Of Medicine	Modulateurs de cdk9 utilises comme cible therapeutique dans l'hypertrophie cardiaque
EP1631268A2 (fr) *	2003-05-21	2006-03-08	Board Of Regents The University Of Texas System	Inhibition de la proteine kinase c-mu (pkd) dans le traitement de l'hypertrophie cardiaque et de l'insuffisance cardiaque
US8309562B2 (en) *	2003-07-03	2012-11-13	Myrexis, Inc.	Compounds and therapeutical use thereof
CN1984660B (zh)	2003-07-03	2010-12-15	美瑞德生物工程公司	作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
DE602004016547D1 (de) *	2003-11-03	2008-10-23	Myogen Inc	1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
EP1685108B1 (fr) *	2003-11-03	2008-07-23	Myogen, Inc.	Composes1,4-dihydropyridine, compositions pharmaceutiques et methodes de traitement des maladies cardiovasculaires
EP1699436A2 (fr) *	2003-12-12	2006-09-13	Myogen, Inc.	Preparations a base d'enoximone et leur utilisation pour traiter l'hypertrophie cardiaque et l'insuffisance cardiaque
WO2005092332A1 (fr) *	2004-03-22	2005-10-06	Myogen, Inc.	Sulfoxyde de (s)-enoximone et son utilisation dans le traitement de maladies mediees par pde-iii
US20060030611A1 (en) *	2004-03-22	2006-02-09	Myogen, Inc.	Enoximone sulfoxide enantiomers and their use in the treatment of PDE-III mediated diseases
CA2572179A1 (fr) *	2004-06-23	2006-01-19	Myogen, Inc.	Formulations d'enoximone et utilisation dans le traitement de maladies a mediation par pde-iii
EP1833482A4 (fr)	2005-01-03	2011-02-16	Myriad Genetics Inc	Composés bicycliques azotés et utilisation thérapeutique associée
US8258145B2 (en) *	2005-01-03	2012-09-04	Myrexis, Inc.	Method of treating brain cancer
WO2007014029A2 (fr) *	2005-07-22	2007-02-01	The Regents Of The University Of Colorado, A Body Corporate	Yin yang 1 utilise comme traitement pour une hypertrophie cardiaque et pour une insuffisance cardiaque
CA2634158A1 (fr) *	2005-12-20	2007-06-28	Gilead Colorado, Inc.	Utilisation de composes de 4,7-dihydrothieno¬2,3-b\|pyridine dans le traitement de maladies cardiovasculaires
ES2397439T3 (es)	2006-08-01	2013-03-07	Board Of Regents Of The University Of Texas System	Identificación de un microARN que activa la expresión de la cadena pesada beta de la miosina
US8440636B2 (en)	2007-07-31	2013-05-14	The Board Of Regents, The University Of Texas System	Micro-RNA family that modulates fibrosis and uses thereof
EP2265291B1 (fr)	2008-03-17	2016-10-19	The Board of Regents of The University of Texas System	Identification des micro-arn dans l'entretien et la régénération de synapses neuromusculaires
US9539427B2 (en)	2010-11-08	2017-01-10	The Johns Hopkins University	Methods for improving heart function
GB2605148A (en) *	2021-03-23	2022-09-28	Vicore Pharma Ab	New compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5671074A (en) *	1979-11-12	1981-06-13	Takeda Chem Ind Ltd	1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4355044A (en) *	1980-12-19	1982-10-19	Bernardo Heller	D-Phenylalanine treatment
US5138069A (en) *	1986-07-11	1992-08-11	E. I. Du Pont De Nemours And Company	Angiotensin II receptor blocking imidazoles
CA1334092C (fr) *	1986-07-11	1995-01-24	David John Carini	Imidazoles bloquant les recepteurs de l'angiotensine ii
SU1518949A1 (ru) *	1987-04-09	1995-04-30	Всесоюзный научно-исследовательский институт химии и технологии лекарственных средств	Способ получения инъекционного раствора 5-этокси-2-этилтиобензимидазола
CA1338238C (fr) *	1988-01-07	1996-04-09	David John Carini	Imidazoles bloquant les recepteurs de l'angiotensine ii et combinaisons de ces imidazoles avec des diuretiques et des anti-inflammatoires non steroidiens
US5015651A (en) *	1988-01-07	1991-05-14	E. I. Du Pont De Nemours And Company	Treatment of hypertension with 1,2,4-angiotensin II antagonists
US5064825A (en) *	1989-06-01	1991-11-12	Merck & Co., Inc.	Angiotensin ii antagonists
DE4010797A1 (de) *	1990-04-04	1991-10-10	Hoechst Ag	Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
NZ238688A (en) *	1990-06-28	1992-05-26	Smithkline Beecham Corp	Substituted histidines: pharmaceutical compositions, preparation and uses thereof
US5135197A (en) *	1990-08-30	1992-08-04	Qualtec Data Products, Inc.	Equipment security method and apparatus
US5126342A (en) *	1990-10-01	1992-06-30	Merck & Co., Inc.	Imidazole angiotensin ii antagonists incorporating acidic functional groups
US5087634A (en) *	1990-10-31	1992-02-11	G. D. Searle & Co.	N-substituted imidazol-2-one compounds for treatment of circulatory disorders
CA2058198A1 (fr) *	1991-01-04	1992-07-05	Adalbert Wagner	Procede de preparation et utilisation de derives d'azole
US5236928A (en) *	1991-03-19	1993-08-17	Merck & Co., Inc.	Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists
CZ36294A3 (en) *	1991-08-19	1994-07-13	Du Pont	Substituted imidazilonone derivatives and pharmaceutical preparations based thereon
DE4221009A1 (de) *	1992-06-26	1994-01-05	Bayer Ag	Imidazolyl-substituierte Cyclohexanderivate
CA2111662C (fr) *	1992-12-17	2004-11-23	Hiroaki Yanagisawa	Derives de biphenyles, leur preparation et leur utilisation pour le traitement de l'hypertension et des maladies cardiaques

1992
- 1992-08-21 TW TW081106607A patent/TW215434B/zh active
- 1992-12-21 CZ CS923811A patent/CZ281983B6/cs not_active IP Right Cessation
- 1992-12-21 SK SK3811-92A patent/SK279109B6/sk unknown
1993
- 1993-03-02 AT AT93103301T patent/ATE230732T1/de active
- 1993-03-02 DE DE59310323T patent/DE59310323D1/de not_active Expired - Lifetime
- 1993-03-02 DK DK93103301T patent/DK0560177T3/da active
- 1993-03-02 EP EP93103301A patent/EP0560177B1/fr not_active Expired - Lifetime
- 1993-03-02 ES ES93103301T patent/ES2187501T3/es not_active Expired - Lifetime
- 1993-03-04 NZ NZ247059A patent/NZ247059A/en unknown
- 1993-03-04 FI FI930970A patent/FI930970A7/fi unknown
- 1993-03-05 PH PH45819A patent/PH31466A/en unknown
- 1993-03-05 ZA ZA931585A patent/ZA931585B/xx unknown
- 1993-03-05 AU AU34011/93A patent/AU663565B2/en not_active Ceased
- 1993-03-05 PL PL93297955A patent/PL173023B1/pl unknown
- 1993-03-05 CN CN93102412A patent/CN1036341C/zh not_active Expired - Fee Related
- 1993-03-05 CA CA002091135A patent/CA2091135A1/fr not_active Abandoned
- 1993-03-05 RU RU93004577A patent/RU2116300C1/ru active
- 1993-03-05 BR BR9300761A patent/BR9300761A/pt not_active Application Discontinuation
- 1993-03-05 JP JP04476993A patent/JP3542813B2/ja not_active Expired - Lifetime
- 1993-03-05 MA MA23107A patent/MA22814A1/fr unknown
- 1993-03-05 KR KR1019930003270A patent/KR930019637A/ko not_active Ceased
- 1993-03-05 NO NO930817A patent/NO303632B1/no unknown
- 1993-03-05 HU HU9300618A patent/HUT64041A/hu unknown
- 1993-03-07 IL IL104971A patent/IL104971A0/xx unknown
1995
- 1995-06-07 US US08/479,561 patent/US5604251A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CZ381192A3 (en)	1993-12-15
NO930817L (no)	1993-09-08
DK0560177T3 (da)	2003-04-14
PH31466A (en)	1998-11-03
BR9300761A (pt)	1993-09-14
DE59310323D1 (de)	2003-02-13
KR930019637A (ko)	1993-10-18
SK381192A3 (en)	1998-06-03
NO930817D0 (no)	1993-03-05
ES2187501T3 (es)	2003-06-16
PL173023B1 (pl)	1998-01-30
CA2091135A1 (fr)	1993-09-08
JP3542813B2 (ja)	2004-07-14
RU2116300C1 (ru)	1998-07-27
HUT64041A (en)	1993-11-29
AU663565B2 (en)	1995-10-12
SK279109B6 (sk)	1998-06-03
HU9300618D0 (en)	1993-05-28
ZA931585B (en)	1993-09-27
PL297955A1 (en)	1993-09-20
NZ247059A (en)	1995-03-28
AU3401193A (en)	1993-09-09
ATE230732T1 (de)	2003-01-15
FI930970A0 (fi)	1993-03-04
TW215434B (fr)	1993-11-01
US5604251A (en)	1997-02-18
CN1036341C (zh)	1997-11-05
EP0560177A1 (fr)	1993-09-15
NO303632B1 (no)	1998-08-10
EP0560177B1 (fr)	2003-01-08
FI930970A7 (fi)	1993-09-08
JPH069572A (ja)	1994-01-18
CZ281983B6 (cs)	1997-04-16
IL104971A0 (en)	1993-07-08
CN1076192A (zh)	1993-09-15

Publication	Publication Date	Title
MA22814A1 (fr)	1993-10-01	Procede de preparation de derives d'imidazole a chaine laterale biphenylsulfonyluree ou biphenylsulfonylurethanne.
DK0533058T3 (da)	2003-11-24	Imidazo-kondenserede iso- og heterocykler som angiotensin-II-antagonister
RU93004577A (ru)	1996-02-27	Производные имидазола с боковой цепью бифенилсульфонилмочевины
EP0784974A4 (fr)	2000-09-27	Dispersion solide ou preparation a dispersion solide de derives xanthine
ATE243697T1 (de)	2003-07-15	Substitutierte heterozyclische derivate als crf antagonisten
ES2179881T3 (es)	2003-02-01	Antagonistas de endotelina.
IL96882A0 (en)	1992-03-29	Uracil derivatives and pesticides containing the same as active ingredient
FI944729L (fi)	1994-10-07	Perhydroisoindolijohdannaiset substanssi P:n antagonisteina
FI935360A0 (fi)	1993-11-30	Guanidinalkyl-1,1-bifosfonsyraderivat, foerfarande foer deras framstaellning samt deras anvaendning
ZA934997B (en)	1995-01-12	Use of 2-(N-(2-aminoethyl)amino)acetic acid derivatives
DE68912438D1 (de)	1994-03-03	Antifungale Antibiotika.
MX10721A (es)	1993-09-01	Procedimiento para la preparacion de derivados de imidazol y producto obtenido.
DE69228307D1 (de)	1999-03-11	Imidazo(1,2-c)chinazolinderivate als antihypertensive und antidysurie
ES2051996T3 (es)	1994-07-01	Producto farmaceutico.
AU3210593A (en)	1993-08-05	Improvements in or relating to organic compounds
FI963568A0 (fi)	1996-09-10	Peptidijohdannaisia
ES2063562T3 (es)	1995-01-01	Uso de 5,6-dihidro-dibenz(b,e)acepina-6,11-dion-11-oximas en la elaboracion de sustancias antirretrovirales.